Krystal Biotech, Inc.
KRYS
$345.70
-$2.40-0.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 64.57% | 81.53% | 129.74% | 279.80% | 38.50% |
| Total Depreciation and Amortization | 9.49% | -18.13% | -23.74% | -44.74% | -50.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.06% | -39.87% | -34.07% | -36.24% | 180.65% |
| Change in Net Operating Assets | 51.45% | 80.15% | -151.91% | -48.13% | 91.19% |
| Cash from Operations | 39.38% | 80.70% | 62.75% | 178.16% | 1,267.39% |
| Capital Expenditure | -46.22% | -40.44% | -182.00% | -100.85% | -65.39% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -- | -99.57% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.17% | 70.39% | 70.54% | -69.37% | -292.67% |
| Cash from Investing | -19.02% | 65.03% | 64.26% | -70.74% | -469.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 353.71% | 54.81% | -30.06% | -71.16% | -78.76% |
| Repurchase of Common Stock | -22.75% | -21.97% | -159.12% | -158.69% | -158.60% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 591.47% | 170.16% | -67.78% | -116.66% | -113.10% |
| Foreign Exchange rate Adjustments | -545.34% | -156.54% | 162.45% | 8,325.00% | 431.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 818.95% | 483.28% | 1,224.85% | 2,470.76% | -88.50% |